Composition : Ramucirumab
Strength availability : 100mg
Pack : 10ml in 1 vial

Cyramza 100mg belongs to Intravenous human monoclonal antibody which prohibits VEGFR2and it increased the haemorrhage risk which may be serious and sometimes fatal. Stop if severe bleeding occurs.
Cyramza 100mg is a prescription drugs which is used under supervision of doctor.


Cyramza 100mg injection indicated for;
• As a single agent, or in concomitant use with paclitaxel for the treatment of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
• In concomitant use with docetaxel for the treatment for metastatic non-small cell lung cancer
• In concomitant use with FOLFIRI for the treatment of patients with metastatic colorectal cancer


Non-Small Cell Lung Cancer :
The usual dose is 10 mg/kg IV infused over ~1 hr prior to docetaxel (75 mg/m²) IV infusion on Day 1 of a 21-day cycle. Continue until disease progression or unacceptable toxicity
Gastric Cancer:
As a monotherapy agent or in co administration with paclitaxel is used.
Usual dose for Single agent or in combination with paclitaxel is 8 mg/kg IV q2wk; infuse over 1 hr
Usual dose for Paclitaxel (if given in combination) is 80 mg/m² once weekly for 3 weeks of every 28-day cycle.
When given in concomitant, administer ramucirumab prior to administration of paclitaxel. Follow until disease progression or unacceptable toxicity
Colorectal Cancer:
In combination with FOLFIRI for the treatment
Usual dose is 8 mg/kg IV q2wk; administer by IV infusion over 60 minutes prior to FOLFIRI administration. Follow until disease progression or unacceptable toxicity


Ramucirumab belongs to vascular endothelial growth factor receptor 2 antagonist which efficiently binds VEGF Receptor 2 and stops binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D.
As a result, ramucirumab prohibits ligand-stimulated activation of VEGF Receptor 2, thereby prohibiting ligand-induced multiplication, and migration of human endothelial cells.
Ramucirumab prevented angiogenesis in an in vivo animal model.
Half-life of ramucirumab 14 days


Increased the risk of haemorrhage and gastrointestinal haemorrhage, containing severe and sometimes fatal haemorrhagic events enduringly discontinue patients who experience severe bleeding
The drug may have high the risk of gastrointestinal perforation, a probably fatal event
Completely stop in patients who experience a gastrointestinal perforation
Impaired wound healing can appear with antibodies prohibiting the VEGF pathway
Avoid in patients with impaired wound healing
Hold up drug prior to surgery and discontinue if a patient occurs wound healing complications


Cyramza 100mg has No clinically meaningful difference in the exposure of either ramucirumab or its combination drugs in the approved combinations, contains paclitaxel, docetaxel, and irinotecan were observed in patients with solid tumor.


Take the dose immediately before next dose duration, Next dose time reaches then left off the missed dose and continue regular schedule. Avoid taking double dose at same time. Please consult the doctor for further information.


Store the vial at 2℃ to 8℃ Discard product if it contains particulate matter, is cloudy, or discoloured Dispose unused portion. Do not store for later use.


• Fatigue/asthenia
• Neutropenia
• Diarrhea
• Epistaxis
• Peripheral edema
• Stomatitis
• Proteinuria
• Hypertension
• Infusion-related reactions
• Hypertension grade 3-4
• Thrombocytopenia
• Hypoalbuminemia .

We'd Like to Hear From You!


1., a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.
2. will not dispense any prescription medication without a valid prescription from a licensed physician.
3. If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.
4. The drug information provided in the is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.
5. requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from
6. At, a Caregiver can order prescription medicines on your behalf.

This information should not be used to decide whether to accept this product or any other medicine. Only a health care provider is knowledge and training to decide that a medicine suitable for a specific patient. This information does not support any drug as safe, are effective or approved for the treatment of any patient or health condition. It's simple a brief overview of general information about this product. It does not include all information on possible applications, indications, warnings, precautions, interactions, adverse effects or risks that may be relevant to this product. This information is not specific medical advice and does not replace information obtained from your health care provider. You should check with your health care provider for complete information about the risks and benefits of using this product.